{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:45:32Z","timestamp":1782589532252,"version":"3.54.5"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C1\/18\/006"],"award-info":[{"award-number":["C1\/18\/006"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/24\/012"],"award-info":[{"award-number":["C16\/24\/012"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["KA\/20\/077"],"award-info":[{"award-number":["KA\/20\/077"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Breakthrough T1D","award":["2-SRA-2022-1200-S-B"],"award-info":[{"award-number":["2-SRA-2022-1200-S-B"]}]},{"name":"Breakthrough T1D","award":["5-CDA-2024-1491-S-B"],"award-info":[{"award-number":["5-CDA-2024-1491-S-B"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1806426N"],"award-info":[{"award-number":["1806426N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G058122N"],"award-info":[{"award-number":["G058122N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00125-026-06750-1","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:46:28Z","timestamp":1779115588000},"page":"2307-2322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-6103","authenticated-orcid":false,"given":"Laure","family":"Degroote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-8622","authenticated-orcid":false,"given":"J\u0119drzej","family":"Chrzanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0687-8685","authenticated-orcid":false,"given":"Pierre","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-8154","authenticated-orcid":false,"given":"Amber","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-0108","authenticated-orcid":false,"given":"Stephanie","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-6893","authenticated-orcid":false,"given":"Annelore","family":"Van Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-6214","authenticated-orcid":false,"given":"Julie","family":"Pierreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-4059","authenticated-orcid":false,"given":"Sophie","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-664X","authenticated-orcid":false,"given":"Lien","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2732-397X","authenticated-orcid":false,"given":"Gunter","family":"Leuckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4452-1928","authenticated-orcid":false,"given":"Marijke","family":"Viaene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7525-7991","authenticated-orcid":false,"given":"Marc","family":"Packbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Douros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-974X","authenticated-orcid":false,"given":"Yves","family":"Heremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-5233","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-3329","authenticated-orcid":false,"given":"Willem","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-6089","authenticated-orcid":false,"given":"Conny","family":"Gysemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0542-5708","authenticated-orcid":false,"given":"Nico","family":"De Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"6750_CR1","doi-asserted-by":"publisher","first-page":"5151171","DOI":"10.1155\/jdr\/5151171","volume":"2024","author":"N Ajmal","year":"2024","unstructured":"Ajmal N, Bogart MC, Khan P, Max-Harry IM, Healy AM, Nunemaker CS (2024) Identifying promising immunomodulators for type 1 diabetes (T1D) and islet transplantation. J Diabetes Res 2024:5151171. https:\/\/doi.org\/10.1155\/jdr\/5151171","journal-title":"J Diabetes Res"},{"key":"6750_CR2","doi-asserted-by":"publisher","first-page":"e240233","DOI":"10.20945\/2359-4292-2024-0233","volume":"68","author":"M Rodacki","year":"2025","unstructured":"Rodacki M, Silva KR, Araujo DB et al (2025) Immunomodulatory agents and cell therapy for patients with type 1 diabetes. Arch Endocrinol Metab 68:e240233. https:\/\/doi.org\/10.20945\/2359-4292-2024-0233","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"6750_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/d41591-022-00115-y","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho T (2023) FDA approves first drug to delay type 1 diabetes. Nat Med 29(2):280. https:\/\/doi.org\/10.1038\/d41591-022-00115-y","journal-title":"Nat Med"},{"issue":"7","key":"6750_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603\u2013613. https:\/\/doi.org\/10.1056\/NEJMoa1902226","journal-title":"N Engl J Med"},{"issue":"583","key":"6750_CR5","doi-asserted-by":"publisher","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","volume":"13","author":"EK Sims","year":"2021","unstructured":"Sims EK, Bundy BN, Stier K et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13(583):eabc8980. https:\/\/doi.org\/10.1126\/scitranslmed.abc8980","journal-title":"Sci Transl Med"},{"issue":"9","key":"6750_CR6","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/jcm9092805","volume":"9","author":"P Beik","year":"2020","unstructured":"Beik P, Ciesielska M, Kucza M et al (2020) Prevention of type 1 diabetes: past experiences and future opportunities. J Clin Med 9(9):2805. https:\/\/doi.org\/10.3390\/jcm9092805","journal-title":"J Clin Med"},{"key":"6750_CR7","unstructured":"Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT (eds) (2023) Diabetes in America. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD"},{"key":"6750_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fendo.2018.00070","volume":"9","author":"LM Jacobsen","year":"2018","unstructured":"Jacobsen LM, Haller MJ, Schatz DA (2018) Understanding pre-type 1 diabetes: the key to prevention. Front Endocrinol (Lausanne) 9:70. https:\/\/doi.org\/10.3389\/fendo.2018.00070","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6750_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S2213-8587(18)30112-8","volume":"7","author":"MA Atkinson","year":"2019","unstructured":"Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M (2019) The challenge of modulating \u03b2-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol 7(1):52\u201364. https:\/\/doi.org\/10.1016\/S2213-8587(18)30112-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6750_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000524866","volume":"96","author":"D Smigoc Schweiger","year":"2023","unstructured":"Smigoc Schweiger D (2023) Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr 96(6):631\u2013645. https:\/\/doi.org\/10.1159\/000524866","journal-title":"Horm Res Paediatr"},{"issue":"12","key":"6750_CR11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.intimp.2010.07.008","volume":"10","author":"T Boettler","year":"2010","unstructured":"Boettler T, von Herrath M (2010) Immunotherapy of type 1 diabetes\u2013how to rationally prioritize combination therapies in T1D. Int Immunopharmacol 10(12):1491\u20131495. https:\/\/doi.org\/10.1016\/j.intimp.2010.07.008","journal-title":"Int Immunopharmacol"},{"key":"6750_CR12","doi-asserted-by":"publisher","first-page":"756548","DOI":"10.3389\/fimmu.2021.756548","volume":"12","author":"E Toren","year":"2021","unstructured":"Toren E, Burnette KS, Banerjee RR, Hunter CS, Tse HM (2021) Partners in crime: beta-cells and autoimmune responses complicit in type 1 diabetes pathogenesis. Front Immunol 12:756548. https:\/\/doi.org\/10.3389\/fimmu.2021.756548","journal-title":"Front Immunol"},{"issue":"7","key":"6750_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","volume":"16","author":"DL Eizirik","year":"2020","unstructured":"Eizirik DL, Pasquali L, Cnop M (2020) Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol 16(7):349\u2013362. https:\/\/doi.org\/10.1038\/s41574-020-0355-7","journal-title":"Nat Rev Endocrinol"},{"key":"6750_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.001","volume":"71","author":"NS Wilcox","year":"2016","unstructured":"Wilcox NS, Rui J, Hebrok M, Herold KC (2016) Life and death of \u03b2 cells in type 1 diabetes: a comprehensive review. J Autoimmun 71:51\u201358. https:\/\/doi.org\/10.1016\/j.jaut.2016.02.001","journal-title":"J Autoimmun"},{"issue":"1","key":"6750_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/JIM.0000000000000229","volume":"64","author":"F Engin","year":"2016","unstructured":"Engin F (2016) ER stress and development of type 1 diabetes. J Investig Med 64(1):2\u20136. https:\/\/doi.org\/10.1097\/JIM.0000000000000229","journal-title":"J Investig Med"},{"key":"6750_CR16","doi-asserted-by":"publisher","first-page":"101365","DOI":"10.1016\/j.molmet.2021.101365","volume":"54","author":"GS Sahin","year":"2021","unstructured":"Sahin GS, Lee H, Engin F (2021) An accomplice more than a mere victim: the impact of \u03b2-cell ER stress on type 1 diabetes pathogenesis. Mol Metab 54:101365. https:\/\/doi.org\/10.1016\/j.molmet.2021.101365","journal-title":"Mol Metab"},{"key":"6750_CR17","doi-asserted-by":"publisher","first-page":"624590","DOI":"10.3389\/fendo.2020.624590","volume":"11","author":"JD Piganelli","year":"2020","unstructured":"Piganelli JD, Mamula MJ, James EA (2020) The role of \u03b2 cell stress and neo-epitopes in the immunopathology of type 1 diabetes. Front Endocrinol (Lausanne) 11:624590. https:\/\/doi.org\/10.3389\/fendo.2020.624590","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6750_CR18","doi-asserted-by":"publisher","first-page":"101998","DOI":"10.1016\/j.molmet.2024.101998","volume":"88","author":"S Roy","year":"2024","unstructured":"Roy S, Pokharel P, Piganelli JD (2024) Decoding the immune dance: unraveling the interplay between beta cells and type 1 diabetes. Mol Metab 88:101998. https:\/\/doi.org\/10.1016\/j.molmet.2024.101998","journal-title":"Mol Metab"},{"issue":"1","key":"6750_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1749-6632.2012.06826.x","volume":"1281","author":"LE Padgett","year":"2013","unstructured":"Padgett LE, Broniowska KA, Hansen PA, Corbett JA, Tse HM (2013) The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 1281(1):16\u201335. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06826.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"6750_CR20","doi-asserted-by":"publisher","first-page":"14669","DOI":"10.1038\/s41598-024-65454-x","volume":"14","author":"AF Mathisen","year":"2024","unstructured":"Mathisen AF, Vacaru AM, Unger L et al (2024) Molecular profiling of NOD mouse islets reveals a novel regulator of insulitis onset. Sci Rep 14(1):14669. https:\/\/doi.org\/10.1038\/s41598-024-65454-x","journal-title":"Sci Rep"},{"issue":"9","key":"6750_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11892-019-1194-6","volume":"19","author":"ASM Moin","year":"2019","unstructured":"Moin ASM, Butler AE (2019) Alterations in beta cell identity in type 1 and type 2 diabetes. Curr Diab Rep 19(9):83. https:\/\/doi.org\/10.1007\/s11892-019-1194-6","journal-title":"Curr Diab Rep"},{"key":"6750_CR22","doi-asserted-by":"publisher","first-page":"103634","DOI":"10.1016\/j.mod.2020.103634","volume":"163","author":"S Balakrishnan","year":"2020","unstructured":"Balakrishnan S, Dhavamani S, Prahalathan C (2020) \u03b2-cell specific transcription factors in the context of diabetes mellitus and \u03b2-cell regeneration. Mech Dev 163:103634. https:\/\/doi.org\/10.1016\/j.mod.2020.103634","journal-title":"Mech Dev"},{"issue":"8","key":"6750_CR23","doi-asserted-by":"publisher","first-page":"e0181651","DOI":"10.1371\/journal.pone.0181651","volume":"12","author":"K Lemaire","year":"2017","unstructured":"Lemaire K, Granvik M, Schraenen A et al (2017) How stable is repression of disallowed genes in pancreatic islets in response to metabolic stress? PLoS One 12(8):e0181651. https:\/\/doi.org\/10.1371\/journal.pone.0181651","journal-title":"PLoS One"},{"issue":"Pt 3","key":"6750_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1042\/BST0360300","volume":"36","author":"R Quintens","year":"2008","unstructured":"Quintens R, Hendrickx N, Lemaire K, Schuit F (2008) Why expression of some genes is disallowed in \u03b2-cells. Biochem Soc Trans 36(Pt 3):300\u2013305. https:\/\/doi.org\/10.1042\/BST0360300","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"6750_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.tem.2024.03.006","volume":"35","author":"S Bourgeois","year":"2024","unstructured":"Bourgeois S, Coenen S, Degroote L et al (2024) Harnessing beta cell regeneration biology for diabetes therapy. Trends Endocrinol Metab 35(11):951\u2013966. https:\/\/doi.org\/10.1016\/j.tem.2024.03.006","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"6750_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00109-024-02494-w","volume":"102","author":"S Lenzen","year":"2024","unstructured":"Lenzen S, J\u00f6rns A (2024) Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches. J Mol Med (Berl) 102(12):1451\u20131455. https:\/\/doi.org\/10.1007\/s00109-024-02494-w","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"6750_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","volume":"17","author":"BO Roep","year":"2021","unstructured":"Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A (2021) Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?). Nat Rev Endocrinol 17(3):150\u2013161. https:\/\/doi.org\/10.1038\/s41574-020-00443-4","journal-title":"Nat Rev Endocrinol"},{"key":"6750_CR28","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne) 15:1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6750_CR29","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res 182:106320. https:\/\/doi.org\/10.1016\/j.phrs.2022.106320","journal-title":"Pharmacol Res"},{"issue":"6","key":"6750_CR30","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M, Usuelli V, Dellepiane S et al (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab 36(6):1302-1319.e1312. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.001","journal-title":"Cell Metab"},{"key":"6750_CR31","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH (2024) Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab 15:20420188231222370. https:\/\/doi.org\/10.1177\/20420188231222367","journal-title":"Ther Adv Endocrinol Metab"},{"key":"6750_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fendo.2018.00672","volume":"9","author":"J Rowlands","year":"2018","unstructured":"Rowlands J, Heng J, Newsholme P, Carlessi R (2018) Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne) 9:672. https:\/\/doi.org\/10.3389\/fendo.2018.00672","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"6750_CR33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2337\/db14-0883","volume":"64","author":"JA Koehler","year":"2015","unstructured":"Koehler JA, Baggio LL, Cao X et al (2015) Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 64(3):1046\u20131056. https:\/\/doi.org\/10.2337\/db14-0883","journal-title":"Diabetes"},{"key":"6750_CR34","doi-asserted-by":"publisher","first-page":"2583047","DOI":"10.1155\/2019\/2583047","volume":"2019","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Hu Y, Xu N et al (2019) A new way for beta cell neogenesis: transdifferentiation from alpha cells induced by glucagon-like peptide 1. J Diabetes Res 2019:2583047. https:\/\/doi.org\/10.1155\/2019\/2583047","journal-title":"J Diabetes Res"},{"key":"6750_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.peptides.2012.10.006","volume":"39","author":"XY Miao","year":"2013","unstructured":"Miao XY, Gu ZY, Liu P et al (2013) The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK\/mTOR\/P70S6K signaling pathway. Peptides 39:71\u201379. https:\/\/doi.org\/10.1016\/j.peptides.2012.10.006","journal-title":"Peptides"},{"issue":"3","key":"6750_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00125-004-1327-5","volume":"47","author":"Q Wang","year":"2004","unstructured":"Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47(3):478\u2013487. https:\/\/doi.org\/10.1007\/s00125-004-1327-5","journal-title":"Diabetologia"},{"issue":"1","key":"6750_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","volume":"52","author":"J Buteau","year":"2003","unstructured":"Buteau J, Foisy S, Joly E, Prentki M (2003) Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52(1):124\u2013132. https:\/\/doi.org\/10.2337\/diabetes.52.1.124","journal-title":"Diabetes"},{"issue":"6","key":"6750_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrendo.2011.242","volume":"8","author":"JP Tiano","year":"2012","unstructured":"Tiano JP, Mauvais-Jarvis F (2012) Importance of oestrogen receptors to preserve functional \u03b2-cell mass in diabetes. Nat Rev Endocrinol 8(6):342\u2013351. https:\/\/doi.org\/10.1038\/nrendo.2011.242","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"6750_CR39","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.2337\/db14-1798","volume":"64","author":"Y Yuchi","year":"2015","unstructured":"Yuchi Y, Cai Y, Legein B et al (2015) Estrogen receptor \u03b1 regulates \u03b2-cell formation during pancreas development and following injury. Diabetes 64(9):3218\u20133228. https:\/\/doi.org\/10.2337\/db14-1798","journal-title":"Diabetes"},{"issue":"7","key":"6750_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/js.2016-1073","volume":"1","author":"T Wu","year":"2017","unstructured":"Wu T, Xu J, Xu S et al (2017) 17\u03b2-estradiol promotes islet cell proliferation in a partial pancreatectomy mouse model. J Endocr Soc 1(7):965\u2013979. https:\/\/doi.org\/10.1210\/js.2016-1073","journal-title":"J Endocr Soc"},{"issue":"5","key":"6750_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1042\/CBI20090390","volume":"34","author":"Z Ren","year":"2010","unstructured":"Ren Z, Zou C, Ji H, Zhang YA (2010) Oestrogen regulates proliferation and differentiation of human islet-derived precursor cells through oestrogen receptor alpha. Cell Biol Int 34(5):523\u2013530. https:\/\/doi.org\/10.1042\/CBI20090390","journal-title":"Cell Biol Int"},{"issue":"6","key":"6750_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1055\/a-0603-3969","volume":"50","author":"S Shaklai","year":"2018","unstructured":"Shaklai S, Grafi-Cohen M, Sharon O et al (2018) Pancreatic beta-cell proliferation induced by estradiol-17\u03b2 is foxo1 dependent. Horm Metab Res 50(6):485\u2013490. https:\/\/doi.org\/10.1055\/a-0603-3969","journal-title":"Horm Metab Res"},{"key":"6750_CR43","unstructured":"Valdes A, Patel P, Bajaj T (2025) Estrogen therapy. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL"},{"key":"6750_CR44","doi-asserted-by":"publisher","first-page":"10211","DOI":"10.1038\/srep10211","volume":"5","author":"JP Tiano","year":"2015","unstructured":"Tiano JP, Tate CR, Yang BS, DiMarchi R, Mauvais-Jarvis F (2015) Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis. Sci Rep 5:10211. https:\/\/doi.org\/10.1038\/srep10211","journal-title":"Sci Rep"},{"issue":"4","key":"6750_CR45","doi-asserted-by":"publisher","first-page":"100598","DOI":"10.1016\/j.xcrm.2022.100598","volume":"3","author":"T Fuselier","year":"2022","unstructured":"Fuselier T, Mota de Sa P, Qadir MMF et al (2022) Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes. Cell Rep Med 3(4):100598. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100598","journal-title":"Cell Rep Med"},{"issue":"3","key":"6750_CR46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s00125-014-3478-3","volume":"58","author":"RW Schwenk","year":"2015","unstructured":"Schwenk RW, Baumeier C, Finan B et al (2015) GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58(3):604\u2013614. https:\/\/doi.org\/10.1007\/s00125-014-3478-3","journal-title":"Diabetologia"},{"issue":"2","key":"6750_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s42255-020-0171-3","volume":"2","author":"S Sachs","year":"2020","unstructured":"Sachs S, Bastidas-Ponce A, Tritschler S et al (2020) Targeted pharmacological therapy restores \u03b2-cell function for diabetes remission. Nat Metab 2(2):192\u2013209. https:\/\/doi.org\/10.1038\/s42255-020-0171-3","journal-title":"Nat Metab"},{"issue":"12","key":"6750_CR48","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/nm.3009","volume":"18","author":"B Finan","year":"2012","unstructured":"Finan B, Yang B, Ottaway N et al (2012) Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18(12):1847\u20131856. https:\/\/doi.org\/10.1038\/nm.3009","journal-title":"Nat Med"},{"issue":"4","key":"6750_CR49","doi-asserted-by":"publisher","first-page":"103492","DOI":"10.1016\/j.xpro.2024.103492","volume":"5","author":"P Lemaitre","year":"2024","unstructured":"Lemaitre P, Mathieu C, Gysemans C (2024) Protocol for murine multi-tissue deep immunophenotyping using a 40-color full-spectrum flow cytometry panel. STAR Protoc 5(4):103492. https:\/\/doi.org\/10.1016\/j.xpro.2024.103492","journal-title":"STAR Protoc"},{"issue":"2","key":"6750_CR50","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00125-025-06604-2","volume":"69","author":"A Wouters","year":"2026","unstructured":"Wouters A, Lemaitre P, Degroote L et al (2026) Redosing of anti-CD3 antibodies in NOD mice with new-onset diabetes does not alter the effect of a single treatment course. Diabetologia 69(2):466\u2013479. https:\/\/doi.org\/10.1007\/s00125-025-06604-2","journal-title":"Diabetologia"},{"key":"6750_CR51","doi-asserted-by":"publisher","first-page":"101188","DOI":"10.1016\/j.molmet.2021.101188","volume":"49","author":"C Salinno","year":"2021","unstructured":"Salinno C, B\u00fcttner M, Cota P et al (2021) CD81 marks immature and dedifferentiated pancreatic \u03b2-cells. Mol Metab 49:101188. https:\/\/doi.org\/10.1016\/j.molmet.2021.101188","journal-title":"Mol Metab"},{"key":"6750_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coi.2016.09.006","volume":"43","author":"AL Clark","year":"2016","unstructured":"Clark AL, Urano F (2016) Endoplasmic reticulum stress in beta cells and autoimmune diabetes. Curr Opin Immunol 43:60\u201366. https:\/\/doi.org\/10.1016\/j.coi.2016.09.006","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"6750_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/03009734.2015.1135217","volume":"121","author":"F Brozzi","year":"2016","unstructured":"Brozzi F, Eizirik DL (2016) ER stress and the decline and fall of pancreatic beta cells in type 1 diabetes. Ups J Med Sci 121(2):133\u2013139. https:\/\/doi.org\/10.3109\/03009734.2015.1135217","journal-title":"Ups J Med Sci"},{"key":"6750_CR54","doi-asserted-by":"publisher","first-page":"1427723","DOI":"10.3389\/fendo.2024.1427723","volume":"15","author":"KL Webster","year":"2024","unstructured":"Webster KL, Mirmira RG (2024) Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival? Front Endocrinol (Lausanne) 15:1427723. https:\/\/doi.org\/10.3389\/fendo.2024.1427723","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"6750_CR55","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.cmet.2020.03.002","volume":"31","author":"H Lee","year":"2020","unstructured":"Lee H, Lee YS, Harenda Q et al (2020) Beta cell dedifferentiation induced by IRE1\u03b1 deletion prevents type 1 diabetes. Cell Metab 31(4):822-836.e825. https:\/\/doi.org\/10.1016\/j.cmet.2020.03.002","journal-title":"Cell Metab"},{"issue":"3","key":"6750_CR56","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cmet.2017.01.005","volume":"25","author":"J Rui","year":"2017","unstructured":"Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC (2017) \u03b2 cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. Cell Metab 25(3):727\u2013738. https:\/\/doi.org\/10.1016\/j.cmet.2017.01.005","journal-title":"Cell Metab"},{"issue":"6","key":"6750_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/dom.12029","volume":"15","author":"TJ Pullen","year":"2013","unstructured":"Pullen TJ, Rutter GA (2013) When less is more: the forbidden fruits of gene repression in the adult \u03b2-cell. Diabetes Obes Metab 15(6):503\u2013512. https:\/\/doi.org\/10.1111\/dom.12029","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"6750_CR58","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","volume":"59","author":"SJ Richardson","year":"2016","unstructured":"Richardson SJ, Rodriguez-Calvo T, Gerling IC et al (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59(11):2448\u20132458. https:\/\/doi.org\/10.1007\/s00125-016-4067-4","journal-title":"Diabetologia"},{"issue":"5","key":"6750_CR59","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/db18-0686","volume":"68","author":"MA Russell","year":"2019","unstructured":"Russell MA, Redick SD, Blodgett DM et al (2019) HLA class II antigen processing and presentation pathway components demonstrated by transcriptome and protein analyses of islet \u03b2-cells from donors with type 1 diabetes. Diabetes 68(5):988\u20131001. https:\/\/doi.org\/10.2337\/db18-0686","journal-title":"Diabetes"},{"key":"6750_CR60","doi-asserted-by":"publisher","first-page":"1414447","DOI":"10.3389\/fendo.2024.1414447","volume":"15","author":"S Patel","year":"2024","unstructured":"Patel S, Remedi MS (2024) Loss of \u03b2-cell identity and dedifferentiation, not an irreversible process? Front Endocrinol (Lausanne) 15:1414447. https:\/\/doi.org\/10.3389\/fendo.2024.1414447","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6750_CR61","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.molmet.2023.101809","volume":"78","author":"EA James","year":"2023","unstructured":"James EA, Joglekar AV, Linnemann AK, Russ HA, Kent SC (2023) The beta cell-immune cell interface in type 1 diabetes (T1D). Mol Metab 78:101809. https:\/\/doi.org\/10.1016\/j.molmet.2023.101809","journal-title":"Mol Metab"},{"key":"6750_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fcell.2015.00067","volume":"3","author":"ML Marr\u00e9","year":"2015","unstructured":"Marr\u00e9 ML, James EA, Piganelli JD (2015) \u03b2 cell ER stress and the implications for immunogenicity in type 1 diabetes. Front Cell Dev Biol 3:67. https:\/\/doi.org\/10.3389\/fcell.2015.00067","journal-title":"Front Cell Dev Biol"},{"key":"6750_CR63","doi-asserted-by":"publisher","first-page":"1393248","DOI":"10.3389\/fimmu.2024.1393248","volume":"15","author":"MC Dekkers","year":"2024","unstructured":"Dekkers MC, Lambooij JM, Pu X et al (2024) Extracellular vesicles derived from stressed beta cells mediate monocyte activation and contribute to islet inflammation. Front Immunol 15:1393248. https:\/\/doi.org\/10.3389\/fimmu.2024.1393248","journal-title":"Front Immunol"},{"issue":"9","key":"6750_CR64","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.cell.2025.02.018","volume":"188","author":"R van Tienhoven","year":"2025","unstructured":"van Tienhoven R, O\u2019Meally D, Scott TA et al (2025) Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay. Cell 188(9):2407-2416.e2409. https:\/\/doi.org\/10.1016\/j.cell.2025.02.018","journal-title":"Cell"},{"issue":"10","key":"6750_CR65","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1172\/JCI79264","volume":"125","author":"RB Sharma","year":"2015","unstructured":"Sharma RB, O\u2019Donnell AC, Stamateris RE et al (2015) Insulin demand regulates \u03b2 cell number via the unfolded protein response. J Clin Invest 125(10):3831\u20133846. https:\/\/doi.org\/10.1172\/JCI79264","journal-title":"J Clin Invest"},{"issue":"4","key":"6750_CR66","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2337\/dc24-2376","volume":"48","author":"AK Desouter","year":"2025","unstructured":"Desouter AK, Keymeulen B, Van de Velde U et al (2025) Repeated OGTT versus continuous glucose monitoring for predicting development of stage 3 type 1 diabetes: a longitudinal analysis. Diabetes Care 48(4):528\u2013536. https:\/\/doi.org\/10.2337\/dc24-2376","journal-title":"Diabetes Care"},{"issue":"9","key":"6750_CR67","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00125-025-06462-y","volume":"68","author":"C Evans-Molina","year":"2025","unstructured":"Evans-Molina C, Dor Y, Lernmark \u00c5 et al (2025) The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment-2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia 68(9):1859\u20131878. https:\/\/doi.org\/10.1007\/s00125-025-06462-y","journal-title":"Diabetologia"},{"issue":"2","key":"6750_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2337\/dc23-1750","volume":"47","author":"TP Foster","year":"2024","unstructured":"Foster TP, Jacobsen LM, Bruggeman B et al (2024) Low-dose antithymocyte globulin: a pragmatic approach to treating stage 2 type 1 diabetes. Diabetes Care 47(2):285\u2013289. https:\/\/doi.org\/10.2337\/dc23-1750","journal-title":"Diabetes Care"},{"issue":"10510","key":"6750_CR69","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(25)01674-5","volume":"406","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Wych J, Hendriks AEJ et al (2025) Minimum effective low dose of antithymocyte globulin in people aged 5\u201325 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet 406(10510):1375\u20131388. https:\/\/doi.org\/10.1016\/S0140-6736(25)01674-5","journal-title":"Lancet"},{"issue":"10","key":"6750_CR70","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00125-025-06490-8","volume":"68","author":"L Degroote","year":"2025","unstructured":"Degroote L, Martens PJ, Viaene M et al (2025) Verapamil and low-dose anti-mouse thymocyte globulin combination therapy stably reverses recent-onset type 1 diabetes in NOD mice by acting on the beta cell and immune axes. Diabetologia 68(10):2263\u20132276. https:\/\/doi.org\/10.1007\/s00125-025-06490-8","journal-title":"Diabetologia"},{"key":"6750_CR71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jaut.2017.07.006","volume":"84","author":"AK Ryd\u00e9n","year":"2017","unstructured":"Ryd\u00e9n AK, Perdue NR, Pagni PP et al (2017) Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes. J Autoimmun 84:65\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2017.07.006","journal-title":"J Autoimmun"},{"issue":"40","key":"6750_CR72","doi-asserted-by":"publisher","first-page":"e2300812","DOI":"10.1002\/adma.202300812","volume":"35","author":"S Jung","year":"2023","unstructured":"Jung S, Ben Nasr M, Bahmani B et al (2023) Nanotargeted delivery of immune therapeutics in type 1 diabetes. Adv Mater 35(40):e2300812. https:\/\/doi.org\/10.1002\/adma.202300812","journal-title":"Adv Mater"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06750-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06750-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:00:21Z","timestamp":1782586821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06750-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["6750"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06750-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to acknowledge the Medical University of Lodz \u2013 Digital Medicine Center (MULDiMediC) project (2023\/ABM\/02\/00009) financed by the Medical Research Agency in Poland for access to its computational resources. We thank A. Demarr\u00e9 and V. Laurysens (BENE, Vrije Universiteit Brussel, Brussels, Belgium) and J. Laureys (Leuven Diabetes Lab, KU Leuven, Leuven, Belgium) for their valuable technical help. We thank N. Vandermeulen and K. Vandereyken (KU Leuven Institute for Single Cell Omics [LISCO], KU Leuven, Leuven, Belgium) for support on the Visium technique. The graphical abstract and Fig.\n                      \n                      a were created with BioRender.com.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The Visium data and code generated in this study are deposited at the RDR repository of KU Leuven and are available via 10.48804\/CBE1UC. Other data that support the findings of this study are available upon request. All data are archived in the VUB\/KUL Institution Data Repository in a FAIR-compliant manner and are available from the corresponding authors upon request. There are no restrictions on data availability.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The codebase is available at\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This work was funded by Breakthrough T1D (2-SRA-2022-1200-S-B: \u2018SyneRegIm: exploring the SYNErgistic effect of beta cell REGeneration and emerging IMmune intervention strategies to prevent and\/or reverse type 1 diabetes\u2019). This work was supported by research and infrastructure grants from KU Leuven (C1\/18\/006 and C16\/24\/012, and KA\/20\/077). This work was supported by grants from the Research Foundation Flanders (FWO) (1806426N and G058122N) and Breakthrough T1D (5-CDA-2024-1491-S-B) to WS. NDL is supported by FWO through grant G099323N. JC is supported by the Foundation for Polish Science START programme, a National Science Centre PRELUDIUM BIS 4 (2022\/47\/O\/NZ5\/00683) grant, a Polish Ministry of Science and Education \u2018Per\u0142y Nauki 1\u2019 (PN\/01\/0025\/2022) grant, an ISPAD-Breakthrough T1D fellowship, CRIDO \u2018Korzenie Przysz\u0142o\u015bci\u2019 and a Medical University of Lodz BRaIn P1 grant. SB, AVM, SC and LW are doctoral fellows from FWO with grant numbers 1S89821N, 11I3123N, 11P3Z24N and 11J7425N, respectively.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet Biomea Fusion, SAB Bio, vTv Therapeutics and Vertex. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from Dexcom, Novo Nordisk and Sanofi. CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of EUDF. All external support of EUDF is to be found on\n                      \n                      . WS serves on the advisory board for Sanofi. Financial compensation for these activities has been received by UZ Brussel. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors have contributed substantially to this study. CM, WS, CG and NDL were responsible for the conceptualisation and design of the project. LD, AW, SB and MV performed the in vivo data curation, while JC and PL conducted the spatial transcriptomics analyses. Figure creation for spatial transcriptomics was done by JC. Immunostaining was carried out by LD, JP, SC, LW and MP. Fiji scripts were designed by LD, AVM and GL, and the immunostaining analyses were performed by LD. Insulitis scorings were conducted by LD and MP. Data were visualised by LD and interpreted by LD, YH, CM, WS, CG and NDL. JDD and BY synthesised, characterised and provided the GLP1-E2 compound and gave scientific input on its use. LD oversaw project administration and prepared the original manuscript draft, and all authors contributed to reviewing and editing the final text. Funding was acquired by CM, WS, CG and NDL. CG and NDL are the guarantors of this work. All authors approved the final version of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}